Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Understanding Alzheimer's Disease: Unraveling the Mysteries of Memory Loss

Stone Albert

Dementia, which is characterized by a decline in thinking and independence in daily tasks, is mostly brought on by Alzheimer's disease (AD), a sickness that results in the degradation of brain cells. The cholinergic and amyloid hypotheses were put up as two key causes of AD, and AD is thought to be a complex illness. The condition is also influenced by a number of risk factors, including as advancing age, hereditary factors, head injuries, vascular diseases, infections, and environmental variables. Only two kinds of medications are now approved to treat AD, cholinesterase enzyme inhibitors and N-methyl d-aspartate antagonists. These medications only work to treat the symptoms of AD; they do not treat the underlying cause of the disease.